DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Azor (Amlodipine Besylate / Olmesartan Medoxomil) - Summary

 
 



USE IN PREGNANCY

When pregnancy is detected, discontinue Azor as soon as possible. When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus [see Warning and Precautions].

 

AZOR SUMMARY

USE IN PREGNANCY

AZOR is a combination of the calcium channel receptor blocker (CCB) amlodipine besylate and the angiotensin II receptor blocker (ARB) olmesartan medoxomil.

AZOR is indicated for the treatment of hypertension, alone or with other antihypertensive agents.


This fixed combination drug is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION).


See all Azor indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Azor (Amlodipine / Olmesartan)

Masked Hypertension Linked to Cognitive Decline
Source: theheart.org | Medscape Cardiology Headlines [2015.05.22]
Ambulatory blood-pressure measurements may reveal "the hidden risk" of diminished cognitive function in older patients, say researchers. In addition, this risk may be increased twofold, they report.
Heartwire from Medscape

New data show need for improved monitoring for pulmonary hypertension following pulmonary embolism
Source: Respiratory / Asthma News From Medical News Today [2015.05.20]
Results from a retrospective cohort study presented at the American Thoracic Society (ATS) 2015 International Conference in Denver found that the incidence of pulmonary hypertension (PH) among...

Managing Hypertension: Technology Challenges Old Habits
Source: MedPage Today Cardiovascular [2015.05.20]
(MedPage Today) -- More accurate automated readings should replace the standard of care in the U.S., says one advocate

American Society of Hypertension (ASH) 2015 Annual Scientific Meeting
Source: theheart.org | Medscape Cardiology Headlines [2015.05.18]
Read clinically focused news coverage of key developments from ASH 2015.
Medscape Cardiology

Odd genetic syndrome suggests increased blood vessel resistance could cause hypertension
Source: Hypertension News From Medical News Today [2015.05.13]
The culmination of two decades of research, a new study reveals the genetic causes of a curious, rare syndrome that manifests as hypertension (high blood pressure) accompanied by short fingers...

more news >>

Published Studies Related to Azor (Amlodipine / Olmesartan)

A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil +/- hydrochlorothiazide. [2011.06]
In the prospective, open-label, titrate-to-goal Blood Pressure Control in All Subgroups With Hypertension (BP-CRUSH) study, 999 patients with hypertension uncontrolled on monotherapy (mean age, 55.6 +/- 11.4 years; baseline blood pressure [BP], 153.7 +/- 9.2/91.9 +/- 8.6 mm Hg) were switched to fixed-dose amlodipine/olmesartan medoxomil (AML/OM) 5/20 mg...

Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies. [2009.01]
BACKGROUND: Most patients with hypertension require more than one drug to attain recommended blood pressure (BP) targets. Initiating therapy with two agents is recommended for patients at high risk of a cardiovascular event or with a BP > 20/10 mmHg above goal. Combination therapy is effective when comprised of agents with complementary mechanisms of action, such as calcium channel blockers (CCBs) and angiotensin II-receptor blockers (ARBs). Two fixed-dose CCB/ARB combinations are approved in the US: amlodipine/valsartan (AML/VAL) and amlodipine/olmesartan medoxomil (AML/OM). OBJECTIVES: To review and describe the efficacy of AML/VAL and AML/OM combinations by discussing similarly designed clinical trials... CONCLUSIONS: This review of published factorial-design studies showed that the maximal marketed doses of an amlodipine/olmesartan medoxomil combination (10/40 mg) and an amlodipine/valsartan combination (10/320 mg) produced large reductions in BP from baseline. Limitations of this review include the small number of studies analyzed and the inherent heterogeneity between patient populations. Further research is warranted to directly compare the efficacy of these combinations in a randomized, controlled trial, or additional published clinical trials are required to provide larger data sets for robust meta-analyses and to overcome heterogeneity observed within these studies.

Changes in biomarkers and 24 hours blood pressure in hypertensive African Americans with the metabolic syndrome: comparison of amlodipine/olmesartan versus hydrochlorothiazide/losartan. [2013]
We evaluated the efficacy of amlodipine and olmesartan (A/O; Azor) versus losartan and hydrochlorothiazide (L/H; Hyzaar), on changes in serum and urine biomarkers of inflammation and oxidation, neutrophil reactive oxygen species generation, and changes in systolic blood pressure (BP), diastolic BP, and heart rate as measured with 24 hours ambulatory BP monitoring in a high-risk, hypertensive African-American population with the metabolic syndrome...

Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity. [2011.06]
A subgroup analysis of a prospective, open-label, single-arm titration study in patients with hypertension and type 2 diabetes or obesity is reported. The primary end point was the change from baseline in mean 24-hour ambulatory systolic blood pressure (BP) after 12 weeks... The SeBP goal of < 130/80 mm Hg was achieved by 26.1% of patients with diabetes and <140/90 mm Hg was achieved by 78.1% of obese patients.

Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. [2011.05.01]
The safety and efficacy of an amlodipine/olmesartan medoxomil (OM)-based titration regimen was assessed in patients with type 2 diabetes mellitus and hypertension. After a 2- to 3-week placebo run-in period, 207 patients received amlodipine 5 mg and were uptitrated to amlodipine/OM 5/20, 5/40, and 10/40 mg and then amlodipine/OM 10/40 mg plus hydrochlorothiazide 12.5 and 25 mg in a step-wise manner at 3-week intervals if the seated blood pressure (BP) remained >/=120/70 mm Hg...

more studies >>

Clinical Trials Related to Azor (Amlodipine / Olmesartan)

A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure [Recruiting]
The initial 12 week portion of this 20 week study will examine the ability of a combination of olmesartan medoxomil and amlodipine to lower the blood pressure of patients with high blood pressure who have not had sufficient blood pressure reduction using one anti-hypertension drug (monotherapy). The final 8 weeks of this 20 week study will examine the ability of a combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide to lower blood pressure in the same patient population. All three medications being tested have been approved by the FDA for the treatment of high blood pressure, but only amlodipine and olmesartan are currently approved for use in combination form.

Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients [Recruiting]

Parallel-Group Comparison of Olmesartan, Amlodipine and Hydrochlorothiazide in Hypertension [Recruiting]
This study is to determine the change in blood pressure from the administration of Olmesartan/Amlodipine/Hydrochlorothiazide triple combinations compared to dual combinations with Olmesartan/Amlodipine.

more trials >>

Reports of Suspected Azor (Amlodipine / Olmesartan) Side Effects

Diarrhoea (6)Dyspnoea (5)Oedema Peripheral (4)Dehydration (4)Hypersensitivity (3)Pruritus (3)Abdominal Discomfort (3)Dizziness (3)Blood Pressure Increased (3)Weight Decreased (2)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 1 ratings/reviews, Azor has an overall score of 8. The effectiveness score is 8 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
 

Azor review by 23 year old female patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   anxiety attacks
Dosage & duration:   0.5g/day (dosage frequency: once a day or when needed) for the period of for a total of eight years now
Other conditions:   chronic back pain
Other drugs taken:   nothing
  
Reported Results
Benefits:   Can get a good nights rest and anxiety attacks are supressed. I have been able to lead a normal life and be successfull. I am doing my doctoral now in medical research and belief without Azor it would not be possible. I remember what my life was before Azor and am relieved to know it is behind me. I have been on it for years now, the benefits outweighs the disadvantages- I know Im addicted. Azor was and still is prescribed to me by my psychiatrist.
Side effects:   Some lethargic tendencies and drowsiness at times when taken for anxiety attack. Also, I am addicted to it. I can not sleep witout Azor.
Comments:   I take one tablet (0.5g) Azor whenever I have a anxiety attack or struggle to sleep. I was attacked a few years back, and still have panic attacks on occasion and struggle to sleep considerably. In addition, I have nightmares. However, when I take the azor, I calm down. Furthermore,I did try sleeping medication, however,I was always tired and struggled to wake up. When I take azor, I can sleep without the whooziness the following morning.

See all Azor reviews / ratings >>

Page last updated: 2015-05-22

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015